Gelesis , a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal GI tract,today announced that the Company will deliver an oral presentation and three poster presentations at ObesityWeek , the annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society in Nashville, Tennessee, from November , The presentations will share data from the pivotal study of Gelesis, an oral, non-systemic approach to weight loss, including data regarding early predictors of clinically meaningful weight loss.
About Gelesis Gelesis is a non-systemic, superabsorbent hydrogel in development for the potential treatment of overweight or obesity.
- Join Kobo & start eReading today!
- The Mechanobiology of Obesity and Related Diseases.
- Yao Fu - Google Scholar Citations?
- How to Disappear: Erase Your Digital Footprint, Leave False Trails, and Vanish without a Trace;
- Gelesis Announces Presentations of Expanded Pivotal Data at ObesityWeek | BioSpace.
- The Mechanobiology of Obesity and Related Diseases - Amit Gefen - Häftad () | Bokus?
- Accident/Incident Prevention;
It is made from two naturally derived building blocks, modified cellulose cross-linked with citric acid, that create a three-dimensional matrix. Orally administered in capsules with water before a meal, Gelesis particles rapidly absorb water in the stomach and homogenously mix with ingested foods.
Passar bra ihop
When hydrated, Gelesis occupies about one-fourth of the average stomach volume. Rather than forming one large mass, it creates thousands of small individual gel pieces with the elasticity firmness of solid ingested foods e. Gelesis maintains its three-dimensional structure and mechanical properties during transit through the small intestine. Once it arrives in the large intestine, the hydrogel is partially broken down by enzymes and loses its three-dimensional structure along with most of its absorption capacity.
The Mechanobiology of Obesity and Related Diseases | KSA | Souq
The released water is reabsorbed in the large intestine, and the remaining cellulosic material is expelled in the feces. Bioengineering has made key contributions to this research field in providing technologies for cell biomechanics experimentation, microscopy and image processing, tissue engineering and multi-scale, multi-physics computational modeling. Topics at the frontier of this field of study include: the continuous monitoring of cell growth, proliferation and differentiation in response to mechanical factors such as stiffness of the extracellular matrix ECM and mechanical loads transferred through the ECM; mechanically-activated signaling pathways and molecular mechanisms; effects of different loading regimes and mechanical environments on differentiation fates of mesenchymal stem cells MSCs into myogenic and osteogenic versus adipogenic lineages; the interactions between nutrition and mechanotransduction; cell morphology, focal adhesion patterns and cytoskeletal remodeling changes in adipogenesis; activation of receptors related to diabetes by mechanical forces; brown and white adipose plasticity and its regulation by mechanical factors.
- [PDF] The Mechanobiology of Obesity and Related Diseases (Studies in Mechanobiology Tissue.
- Innovative mechanobiology research expands understanding of cells;
- Publications – Lee Lab @ Tufts.
- The Mechanobiology of Obesity and Related Diseases | SpringerLink;
- Full Gelesis Data Published in the Journal Obesity - RNS - London Stock Exchange.
- New technology allows researchers to probe cell changes without disturbing the cell's physiology.
Engineering Biomedical Engineering. Describes the state-of-knowledge in the study of the relationships between mechanical loading states in tissues and common pathophysiologies Includes the important topics at the frontier of this field Written by important scientists in the field see more benefits. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
PureTech Health plc published this content on 13 November and is solely responsible for the information contained herein. Log in. E-mail Password Remember Forgot password? Sign up. New member.
United States. United Kingdom. Schweiz DE. Suisse FR. Latest News. Listed company. Sector News.
Pivotal Weight Loss Data for Gelesis100 Published in Obesity, Including Predictors of Response
Our View. All Analysis. Stock Picks. All stock picks.
My Portfolio. Stock Screener Home. Technical Analysis. My Watchlists. Top News. Top Fundamentals.
Top Technicals. Top Movers. Stock Screener. Our Services. MarketScreener Portfolios.
Gelesis Awarded $10.6 (€9.4) Million Grant to Support Commercial Manufacturing of PLENITY™
Add to my list. Manage my lists. About Gelesis Gelesis is a non-systemic, superabsorbent hydrogel in development for the potential treatment of overweight or obesity. About Gelesis Gelesis is developing a novel mechanobiology platform technology to treat obesity and other chronic diseases related to the GI pathway. Forward Looking Statement This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies.
Attachments Original document Permalink. Disclaimer PureTech Health plc published this content on 13 November and is solely responsible for the information contained herein. Financials USD. More Financials.
Period : Day Week. Technical analysis.